RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Magenta Therapeutics Stock

Magenta Therapeutics ROE 2024

Magenta Therapeutics ROE

-0.72

Ticker

MGTA

ISIN

US55910K1088

WKN

A2JPD6

In 2024, Magenta Therapeutics's return on equity (ROE) was -0.72, a 75.16% increase from the -0.41 ROE in the previous year.

Magenta Therapeutics Aktienanalyse

What does Magenta Therapeutics do?

Magenta Therapeutics Inc is a groundbreaking biotechnology company specializing in the development of novel therapies for serious blood disorders. The company uses a unique technology platform based on stem cell transplantation and gene editing to develop innovative therapies that have the potential to improve the lives of millions of people worldwide. Magenta Therapeutics was founded in 2016 by an experienced team of executives and scientists who had previously worked in various biotech companies. The company is headquartered in Cambridge, Massachusetts, USA and has been listed on the NASDAQ stock exchange since 2018. Its business model is based on the development and commercialization of innovative therapies for blood diseases, based on a stem cell technology platform and gene editing technology. These technologies are intended to improve the treatment of blood diseases and enhance the quality of life for patients. Magenta Therapeutics has a comprehensive portfolio of therapy candidates targeting various aspects of stem cell transplantation and gene editing. These therapies aim to reduce the risks and burdens of traditional stem cell transplantation while fully harnessing the potential of stem cell transplantation to cure or alleviate blood diseases. The company has three major business areas: stem cell therapy, gene therapy, and cell therapy. In the context of these business areas, Magenta Therapeutics has already developed several therapy candidates that are currently in various stages of clinical development. The company's work is supported by a variety of financial investors, including some of the most respected names in the biotech industry. Magenta Therapeutics is also actively involved in developing partnerships with other leading companies in the biotechnology industry to further leverage the potential of its platform technology. In conclusion, Magenta Therapeutics is a young and innovative company focused on developing and commercializing new groundbreaking therapies for blood diseases. With its approach of combining stem cell technology and gene editing, the company has the potential to improve the lives of millions of patients with blood diseases while also achieving a significant return for its investors. Magenta Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Magenta Therapeutics's Return on Equity (ROE)

Magenta Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Magenta Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Magenta Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Magenta Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Magenta Therapeutics stock

What is the ROE (Return on Equity) of Magenta Therapeutics this year?

The ROE of Magenta Therapeutics this year is -0.72 undefined.

How has the Return on Equity (ROE) of Magenta Therapeutics developed compared to the previous year?

The ROE of Magenta Therapeutics has increased by 75.16% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Magenta Therapeutics?

A high ROE indicates that Magenta Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Magenta Therapeutics?

A low ROE can indicate that Magenta Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Magenta Therapeutics affect the company?

A change in ROE (Return on Equity) of Magenta Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Magenta Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Magenta Therapeutics?

Some factors that can influence Magenta Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Magenta Therapeutics pay?

Over the past 12 months, Magenta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Magenta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Magenta Therapeutics?

The current dividend yield of Magenta Therapeutics is .

When does Magenta Therapeutics pay dividends?

Magenta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Magenta Therapeutics?

Magenta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Magenta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Magenta Therapeutics located?

Magenta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Magenta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Magenta Therapeutics from 8/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/17/2024.

When did Magenta Therapeutics pay the last dividend?

The last dividend was paid out on 8/17/2024.

What was the dividend of Magenta Therapeutics in the year 2023?

In the year 2023, Magenta Therapeutics distributed 0 USD as dividends.

In which currency does Magenta Therapeutics pay out the dividend?

The dividends of Magenta Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Magenta Therapeutics

Our stock analysis for Magenta Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Magenta Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.